Indian Institute of Science founded Strand Life Sciences in partnership with the Mazumdar-Shaw Medical Foundation has developed a cancer diagnostic kit that can assess the likely occurrence of the chronic disease at one-fourth of the current diagnostic costs.
Bangalore-based Strand, a technology company in the field of genomics, has patented intellectual property to help early detection of breast and ovarian cancer among Indian patients by analyzing DNA sequences.
Heredity is a major factor in the recurrence of cancer through generations. Brca I, Brca II, and TP53 are the three genes that can mutate and cause breast or ovarian cancer.
Breast cancer is the most prevalent cancer among Indian women with approximately 1.5 lakh new patients being diagnosed every year. Nearly 7 lakh Indians die of some form of cancer every year, while over 10 lakh are newly diag nosed with the disease.
Strand's cancer detection tests will be carried out at the Mazumdar-Shaw Centre for Translational Research located in Electronics City , at a cost of Rs 15,000 per screening.
The results of the test would be delivered in two to three weeks. Dr Vijay Chandru, chairman and CEO of Strand Life Sciences, said the company was able to re-engineer costs using its core strength of bioinformatics (applying computer science, statistics, mathematics and engineering to process biological data) and lowering the cost of chemical reagents used in the test by 30% to 40%.
Cancer detection tests using traditional technology cost between Rs 50,000 and Rs 80,000 in India and about $2,000 to $3,000 abroad, said Dr Chandru. “This test would only be carried out on a doctor's prescription, typically a family doctor who knows the history of the patient,“ he said, adding that many citizens were being led astray by fly-bynight operators who advertise similar tests but do others.Source
Times Of India
22 April 2014